COIOSDeep risk insights through multi-disciplinary research across the globe
A group of sailboats sailing on a lake in front of a city
Item refines Peer-reviewed Added

Statin intolerance is often followed by stopping all lipid-lowering therapy

In a US health system, 39.9% of patients with documented statin intolerance stopped all lipid-lowering therapy within 90 days.

Of 254,035 new statin users at Mass General Brigham, 10,644 (4.2%) developed clinician-documented intolerance after a median 3.1 years. Within 90 days, 39.9% stopped all lipid-lowering therapy and fewer than 10% received a nonstatin-based strategy. At 3 to 6 months, mean LDL cholesterol rose 6.8 mg/dL in discontinuers and fell 4.9 mg/dL in continuers. Against statin-tolerant patients, intolerance had hazard ratios of 1.12 to 1.55 for revascularisation, myocardial infarction and ischaemic stroke. Among intolerant patients, stopping all therapy had hazard ratios from 1.38 for death to 2.14 for venous thromboembolism. The time-varying Cox analysis is observational and from one health system, so those who stopped may differ in other ways.

Why it is interesting: Two in five patients recorded as statin-intolerant stopped all lipid-lowering treatment within 90 days. Those who stopped had rising LDL cholesterol and higher risk of every outcome than those continuing any.

Source
Journal of the American Heart Association, 2 November 2026
Paper
Statin Intolerance, Treatment Gaps, and Cardiovascular Outcomes: A 24-Year Health System Analysis
Authors
Supriami K, Akl EW, Abou-Karam R, Thompson AG, Yudelman M, Atlas SJ et al.
DOI
10.1161/JAHA.126.053967
Type
Peer-reviewed article
Design
Retrospective EHR cohort of 254,035 new statin users, Mass General Brigham, records 1987–2025 (trends 2001–2024), time-varying Cox models
Verdict
Refines prior evidence
Driver
Heart and stroke
Driver
Adherence and persistence

Other drivers in Health today